|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
1,770,000,000 |
Market
Cap: |
319.22(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$132.51 - $181.2 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 560 |
Guru Rank Value : 3 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
459,004 |
461,916 |
572,567 |
1,579,317 |
Total Sell Value |
$81,195,771 |
$81,646,316 |
$98,508,149 |
$252,708,726 |
Total People Sold |
9 |
9 |
10 |
14 |
Total Sell Transactions |
10 |
11 |
17 |
37 |
End Date |
2023-12-28 |
2023-09-26 |
2023-03-28 |
2022-03-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Donoghoe Nicholas |
EVP, CHIEF BUS/STRAT OFFICER |
|
2024-03-20 |
4 |
S |
$176.30 |
$3,716,757 |
D/D |
(21,082) |
55,903 |
|
-2% |
|
Stewart Jeffrey Ryan |
EVP, CHIEF COMMERCIAL OFFICER |
|
2024-03-18 |
4 |
S |
$178.69 |
$10,539,508 |
D/D |
(58,949) |
60,941 |
|
-0% |
|
Stewart Jeffrey Ryan |
EVP, CHIEF COMMERCIAL OFFICER |
|
2024-03-18 |
4 |
OE |
$61.36 |
$1,602,110 |
D/D |
26,110 |
119,890 |
|
- |
|
Richmond Timothy J. |
EVP, CHIEF HR OFFICER |
|
2024-03-01 |
4 |
AS |
$176.35 |
$13,415,503 |
D/D |
(75,680) |
13,837 |
|
-0% |
|
Richmond Timothy J. |
EVP, CHIEF HR OFFICER |
|
2024-03-01 |
4 |
OE |
$61.36 |
$2,804,152 |
D/D |
45,700 |
89,517 |
|
- |
|
Buckbee Kevin K |
SVP, CONTROLLER |
|
2024-02-29 |
4 |
S |
$176.65 |
$908,688 |
D/D |
(5,144) |
6,983 |
|
-2% |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2024-02-29 |
4 |
AS |
$177.05 |
$1,754,555 |
D/D |
(9,891) |
10,397 |
|
1% |
|
Michael Robert A. |
PRES & CHIEF OPERATING OFFICER |
|
2024-02-29 |
4 |
S |
$176.44 |
$12,153,957 |
D/D |
(68,879) |
98,645 |
|
-2% |
|
Michael Robert A. |
PRES & CHIEF OPERATING OFFICER |
|
2024-02-29 |
4 |
OE |
$54.86 |
$1,257,012 |
D/D |
21,560 |
167,524 |
|
- |
|
Stewart Jeffrey Ryan |
EVP, CHIEF COMMERCIAL OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$4,675,398 |
D/D |
(26,121) |
93,780 |
|
- |
|
Richmond Timothy J. |
EVP, CHIEF HR OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$4,268,375 |
D/D |
(23,847) |
43,817 |
|
- |
|
Buckbee Kevin K |
SVP, CONTROLLER |
|
2024-02-28 |
4 |
D |
$178.99 |
$955,628 |
D/D |
(5,339) |
13,872 |
|
- |
|
Hudson Thomas J |
SVP, CSO, GLOBAL RESEARCH |
|
2024-02-28 |
4 |
D |
$178.99 |
$3,693,280 |
D/D |
(20,634) |
107,267 |
|
- |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2024-02-28 |
4 |
D |
$178.99 |
$1,411,336 |
D/D |
(7,885) |
20,288 |
|
- |
|
Saleki-Gerhardt Azita |
EVP, CHIEF OPERATIONS OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$4,289,674 |
D/D |
(23,966) |
219,978 |
|
- |
|
Thakkar Roopal |
SVP, CMO, GLOBAL THERAPEUTICS |
|
2024-02-28 |
4 |
D |
$178.99 |
$879,557 |
D/D |
(4,914) |
23,259 |
|
- |
|
Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$2,082,370 |
D/D |
(11,634) |
15,431 |
|
- |
|
Donoghoe Nicholas |
EVP, CHIEF BUS/STRAT OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$3,001,841 |
D/D |
(16,771) |
76,985 |
|
- |
|
Michael Robert A. |
PRES & CHIEF OPERATING OFFICER |
|
2024-02-28 |
4 |
D |
$178.99 |
$6,736,826 |
D/D |
(37,638) |
145,964 |
|
- |
|
Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
|
2024-02-28 |
4 |
S |
$177.27 |
$24,572,458 |
D/D |
(138,616) |
519,099 |
|
-1% |
|
Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
|
2024-02-28 |
4 |
D |
$178.99 |
$19,733,469 |
D/D |
(110,249) |
657,715 |
|
- |
|
Gonzalez Richard A |
CHAIRMAN OF THE BOARD AND CEO |
|
2024-02-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,195 |
767,964 |
|
- |
|
Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
|
2024-02-23 |
4 |
S |
$177.44 |
$2,509,002 |
D/D |
(14,140) |
27,065 |
|
-1% |
|
Reents Scott T |
EVP, CHIEF FINANCIAL OFFICER |
|
2024-02-23 |
4 |
OE |
$61.36 |
$867,630 |
D/D |
14,140 |
41,205 |
|
- |
|
Siatis Perry C |
EVP, GC AND SECRETARY |
|
2024-02-23 |
4 |
AS |
$177.51 |
$2,441,295 |
D/D |
(13,753) |
28,173 |
|
0% |
|
641 Records found
|
|
Page 1 of 26 |
|
|